VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) — Ranovina Therapeutics Inc. (“Sink” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer treatments through drug discovery using artificial intelligence, today announced that its President and Chief Scientific Officer Professor Mads Daugaard has been invited to speak and participate as an expert in 9th Annual DNA Damage Response (DDR) Summitwhich will take place January 27-29, 2026 in Boston, MA.
The DDR Inhibitors Summit is recognized as the premier global forum bringing together scientists, clinicians and biotechnology innovators working to advance next-generation cancer treatments targeting DDR. The 2026 program will provide expertise on synthetic lethality, novel RDR drug targets, biomarkers and artificial intelligence-driven discoveries, with a focus on translational strategies to accelerate clinical impact.
Professor Daugaard will give a thematic presentation on the topic:
“Using Artificial Intelligence-Driven Drug Discovery to Accelerate the Development of Next-Generation DDR Drugs”
His session will highlight Rakovina's turn to the AI-driven model of drug discovery and showcase research on AI-powered DDR programs moving through preclinical screening by leading experts and leading to development.
In addition to his presentation, Professor Daugaard will participate in a fireside chat entitled “Empowering academic entrepreneurs to translate RDR discoveries into impactful biotechnology ventures” and panel discussion on “Bringing together founders and funders to align scientific vision with investment strategy.” In these sessions, he will join a distinguished panel of global oncology leaders to discuss the evolving biology of DDR, mechanisms of resistance, and next-generation clinical strategies.
“The field of DDR is undergoing profound changes driven by new discoveries in DNA damage response biology, smarter combination strategies, and the integration of AI into early discoveries,” said Professor Daugaard. “We are excited to contribute to the scientific dialogue shaping the future of targeted oncology and share how AI can accelerate the development of precisely engineered DDR therapeutics for clinical impact.”
As Co-Founder of Conch and Associate Professor at the University of British Columbia, Professor Daugaard has deep expertise in cancer biology and therapeutic resistance, with a particular focus on identifying vulnerabilities in tumor survival pathways and advancing them towards the development of targeted drugs. Its participation in the 9th DDR Inhibitors Summit reinforces the momentum behind the development of the AI-powered DDR Shell and highlights the company's role in the collaborative global effort to bring new therapeutic options to patients with difficult-to-treat cancers.
About Sink Therapeutics Inc.
Ranovina Therapeutics is a biopharmaceutical research company focused on developing innovative cancer treatments. Our work is based on unique DNA damage response technologies powered by artificial intelligence (AI) using our proprietary Deep-Docking™ and Enki™ platforms. Using AI, we can screen and optimize drug candidates much faster than ever before.
The Company has created a pipeline of unique DNA damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. More information can be found at www.rakovinatherapeutics.com..
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Notice regarding Ranovina Therapeutics' forward-looking statements:
This release includes forward-looking statements regarding the company and its related business, which may include, without limitation, statements regarding the company's proposed business plan and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “expects,” “anticipates,” “scheduled,” “intends,” “considers,” “anticipates,” “believes,” “proposes,” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may,” “could,” “will,” “could,” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of company management. The forward-looking events and circumstances discussed in this press release may not occur on certain dates indicated, or at all, and may differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks associated with the biopharmaceutical industry, economic factors, regulatory factors, equity markets generally, and risks associated with growth and competition.
Although the company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that could cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete discussion of all applicable risk factors and their potential consequences, the reader is encouraged to consult the Company's most recent filings on SEDAR+, copies of which can be found on the Company's profile page at www.sedar.com.
For more information contact:
Michelle Seltenrich, MBA
Director of Corporate Development
[email protected]
778-773-5432
